Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that parent(s)/Legally Acceptable Representatives (LAR) can and will comply with the requirements of the protocol.~* A male or female between, and including, 13 and 15 months of age at the time of the first vaccination.~* Written informed consent obtained from the parent(s)/ LAR of the subject.~* Healthy subjects as established by medical history and clinical examination before entering into the study.~Exclusion Criteria:~* Child in care.~* Use of any investigational or non-registered product other than the study vaccines within 30 days preceding the dose of study vaccine, or planned use during the study period.~* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.~* Planned administration/ administration of a vaccine not foreseen by the study protocol starting 30 days prior to the study vaccination/s and ending 42 days after the vaccination/s (at Visit 2), with the exception of inactivated influenza (flu) vaccine, which may be given at any time during the study, including the day of study vaccination/s.~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.~* Previous vaccination against measles, mumps, rubella, varicella/ herpes zoster and/or N. meningitidis serogroup C.~* History of measles, mumps, rubella, varicella and/or N. meningitidis serogroup C diseases.~* Known exposure to measles, mumps, rubella and or varicella starting 30 days prior to enrolment.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.~* Family history of congenital or hereditary immunodeficiency.~* History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine(s).~* Major congenital defects or serious chronic illness.~* Acute disease and/or fever at the time of enrollment.~* Documented human immunodeficiency virus (HIV) positive subject.~* Any contraindications as stated in the Summary of Product Characteristics.~* Administration of immunoglobulins and/or any blood products within three months prior to the first vaccine dose or planned administration during the study period.

- Gender: ALL
- Minimum Age: 13 Months
- Maximum Age: 15 Months
- Healthy Volunteers: t

Study Arms:
- Group A (Type: ACTIVE_COMPARATOR): Subjects in this arm will receive MMRV vaccine at Visit 1 (Day 0) and MenC vaccine at Visit 2 (Days 35-49).
- Group B (Type: EXPERIMENTAL): Subjects will receive MMRV vaccine and MenC vaccine at Visit 1 (Day 0).
- Group C (Type: ACTIVE_COMPARATOR): Subjects will receive Men C vaccine at Visit 1 (Day 0) and MMRV vaccine at Visit 2 (Day 35-49).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete